IMC Chicago’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.25M Sell
16,500
-6,900
-29% -$848K ﹤0.01% 2908
2026
Q1
$2.76M Sell
23,400
-3,800
-14% -$531K ﹤0.01% 2296
2025
Q4
$4.46M Buy
27,200
+16,700
+159% +$2.62M ﹤0.01% 1818
2025
Q3
$1.4M Buy
+10,500
New +$1.28M ﹤0.01% 2483
2025
Q2
Sell
-13,100
Closed -$1.67M 3540
2025
Q1
$1.67M Sell
13,100
-16,700
-56% -$2.57M ﹤0.01% 1925
2024
Q4
$4.29M Buy
29,800
+2,400
+9% +$344K ﹤0.01% 1336
2024
Q3
$4.08M Buy
27,400
+8,000
+41% +$1.15M ﹤0.01% 1232
2024
Q2
$2.45M Buy
+19,400
New +$3.04M ﹤0.01% 1446

Other funds holding RGEN

IMC Chicago's RGEN Position: Q2 2026 in Review

IMC Chicago sold out of Repligen (RGEN) in Q2 2026, closing a stake of 9,012 shares — an estimated $1.11M sold.

IMC Chicago first reported a position in RGEN in Q1 2026 and held it in 1 quarter. The position peaked at $1.06M in Q1 2026. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • IMC Chicago reported no remaining Repligen position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 9,012 Repligen shares in Q2 2026, an estimated $1.11M.
  • IMC Chicago first reported a position in Repligen in Q1 2026 and held it in 1 quarter.
  • IMC Chicago's Repligen position peaked at $1.06M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.